Completed PHASE4 NCT00219284

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off

Sponsor: Novartis Pharmaceuticals

Conditions Parkinson's Disease With End of Dose Wearing Off

Interventions Carbidopa/levodopa/entacapone

Updated 6 times since 2017 Last updated: Feb 28, 2017 Started: Jan 31, 2005 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

Listed as NCT00219284, this PHASE4 trial focuses on Parkinson's Disease With End of Dose Wearing Off and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bellevue, United States , Bingham Farms, United States , Boca Raton, United States , Bradenton, United States , Canton, United States , Caroline, Puerto Rico , Chicago, United States , Columbia, United States , Commack, United States and 32 more locations